Radiation Oncology

EmailEmail    |   Bookmark Page Bookmark  |   RSS Feeds RSS  |   Print Page Print  

Research Presented in 2013

2013 Gastrointestinal Cancers Symposium
January 24-26, 2013
San Francisco, CA

  • Local control in resectable and borderline resectable pancreatic cancer treated with preoperative chemoradiation using IMRT or chemotherapy alone. J Kharofa, T Kelly, B George, S Tsai, P Ritch, L Wiebe, K Christians, D Evans, B Erickson. 

Society of Surgical Oncology
66th Annual Cancer Symposium
March 6-9, 2013
National Harbor, MD

  • Minimal differences in biomarker profiling of resected pancreatic adenocarcinoma between patients receiving neoadjuvant therapy and those treated with surgery first. CH Pilgrim, AF Mahmoud, KK Christians, SG Pappas, KK Turaga, E Quebbeman, T Gamblin, B George, B Erickson, T Kelly, P Ritch, D Evans S Tsai.
  • Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the presence of extra-hepatic disease. M Hwang D Green, RT Groeschl, SG Pappas, JP Thomas, B Erickson, T Gamblin, KK Turaga.

American Brachytherapy Society (ABS)
Annual Meeting
April 18-20, 2013
New Orleans, LA

  • Points vs. volumes? Doses to organs-at-risk in intracavitary HDR brachytherapy for cervical cancer. JR Bagley, T Kelly, J Rownd, N Morrow, B Erickson.
  • 3-Tesla MRI based adaptive brachytherapy (MRIB-ABT) for cervix cancer: Treatment technique and initial clinical outcomes. J Kharofa, N Morrow, T Kelly, J Rownd, E Paulson, B Erickson.  

International Society for Magnetic Resonance in Medicine (ISMRM)
21st Annual Meeting
April 20-26, 2013
Salt Lake City, UT

  • Dynamic susceptibility contrast MRI measures of standardized rCBV Predict Response to Bevacizumab in High-Grade Brain Tumor Patients. KM Schmainda, M Prah, J Connelly, SD Rand, PS LaViolette, ES Paulson, W Mueller, GM Malkin.
  • Repeatability of standardized and normalized rCBV in patients with newly diagnosed GBM. M Prah, ES Paulson, D Jennings, E Gerstner, T Batchelor, S Stufflebeam, KM Schmainda. 

American Radium Society
95th Annual Meeting
April 27-May 1, 2013

Pheonix, AZ

  • Effect of treatment modality on the hypothalamic-pituitary function of patients treated with radiation therapy for pituitary adenomas; effect of hypothalamic dose on endocrine outcomes. PD Leo, M Franczak M, S Berentsen J Bovi, PS LaViolette, C Schultz, D Sabsevitz. AZ.

American Society of Clinical Oncology (ASCO)
2013 Annual Meeting
May 31-June 4, 2013
Chicago, IL

  • Pre-irradiation chemotherapy with methotrexate, rituximab, and temozolomide and post-irradiation temozolomide for primary central nervous system lymphoma: RTOG 0227 phase II study results. J Glass, M Won, C Schultz, D Brat, N Bartlett, J Suh, B Fisher, M Liepman, M Mehta.
  • p16 expression as a human papillomavirus (HPV) - independent prognostic biomarker in non-oropharyngeal squamous cell carcinoma (non-OPSCC). C Chung E Zhang E, C Kong, J Harris, K Ang, P Hari, D Wang, K Redmond, G Shenouda, A Trott, D Raben, M Gillison, R Jordan, Q Le.
  • RTOG 0618: Stereotactic body radiation therapy (SBRT) to treat operable early stage lung cancer patients.  R Timmerman, R Paulus, H Pass, E Gore, M Edelman, J Galvin, H Choy, W Straube, LA Nedzi, R McGarry, CG Robinson, P Schiff, J Bradley.

American Academy of Clinical Neuropsychology (AACN)
11th Annual Meeting
June 19-22, 2013
Chicago, IL

  • A quantitative study of cerebral atrophy following whole brain radiation therapy.  P Leo, M Franczak, S Beentsen, J Bovi, P LaViolette, C Schultz, D Sabsevitz.

American Association of Physicists in Medicine (AAPM)
55th Annual Meeting
August 4-8, 2013
Indianapolis, IN

  • Feasibility of MR relaxometry-guided synthetic CT image formation for MRI-based radiation treatment planning.  ES Paulson.
  • Improving target delineation by using deformably registered multi-modality images for radiation therapy of pancreatic cancer. C Yang, I  Moraru,  E Dalah, V Hart, ES Paulson, B Erickson, XA Li.
  • Impact of partial volume effect for using PET to define metabolically active tumor volume for pancreatic cancer. E Dalah, C Yang, I Moraru, ES Paulson, B Erickson, XA Li.
  • Online adaptive replanning for sequential boost after whole breast irradiation. X Chen, Q Qiao, A Currey, JE Nascimento, JF Wilson, XA Li.
  • Dosimetric assessment of a new multi-center protocol for radiotherapy of multiple ipsilateral breast cancers. G Chen, A Currey, XA Li.
  • Dosimetric impact of interfractional anatomy changes on breast radiotherapy based on accumulative dose: IMRT vs 3D CRT. NM Morrow, E Ahunbay, A Currey, XA Li.
  • Modeling normal tissue complication probability based on compiled clinical data from skin cancer radiotherapy. P Prior, JF Wilson, XA Li.
  • Extracting patient specific radiobiological parameters from tumor regression for biologically-based adaptive radiation therapy of head and neck cancer. A Tai, C Schultz, XA Li.
  • Dosimetric benefits of online adaptive replanning for lung cancer with multiple targets. F Liu, A Tai, E Ahunbay, E Gore, C Johnstone, XA Li.
  • Plan quality of proton vs. photon IMRT for whole ventricle irradiation. K Kainz, WA Wang, S Firat, JF Wilson, C Schultz, XA Li.
  • Increasing soft tissue contrast with CT dose for radiation treatment planning and delivery guidance. G Chen, A Tai, F Liu, H Shukla, B Erickson, XA Li. 
  • Deformable registration of CT and ultrasound image for radiation treatment of skin cancer. V Hart, T Liu, K Fishman, JF Wilson, XA Li.

American Society of Therapeutic Radiology and Oncology (ASTRO)
55th Annual Meeting
September 22-25, 2013
Atlanta, GA

  • Radiation therapy oncology group (RTOG) 9413: A randomized trial comparing whole pelvic radiotherapy (WPRT) to prostate only (PORT) & neoadjuvant hormonal therapy (NHT) to adjuvant hormonal therapy (AHT).  M Roach III, D Hunt, CA Lawton, ICJ Hsu, RA Lustig, CU Jones, M Rotman, KL Zeitzer, M Werner-Wasik, H Kim, CR Thomas Jr, WU Shipley, HM Sandler.
  • Toxicities and survival of elderly patients with muscle-invasive bladder cancer treated with definitive bladder preservation therapy. DP Lindsay, J Kharofa, C Lawton, K Bylow, P Langenstroer, W See, D Wang.
  • Significant reduction of salivary gland volumes after the first two-week standard fractionation IMRT for head and neck cancer. J Yi, E Ahunbay, Z Li, C Schultz, D Wang.
  • Local control in resectable and borderline resectable pancreatic cancer (PCa) treated with preoperative chemoradiation or chemotherapy alone. J Kharofa, T Kelly, B George, S Tsai, P Ritch, K Christians, D Evans, B Erickson.
  • Toxicity of continuous course re-irradiation concurrent with weekly cisplatinum and cetuximab for recurrent squamous cell carcinoma of the head and neck: Report of a phase II trial. LA Nedzi, M Yao, D Wang, B Sumer, R Hughes, P Lavartu, S Wong, L Myers, J Yordy, J Truelson.
  • Significant reduction of radiation related morbidities in the extremity sarcoma patients treated with image-guided radiotherapy to reduced target volume: results of RTOG 0630. D Wang, Q Zhang, BL Eisenberg, JM Kane, XA Li, D Lucas, CR Freeman,  A Trott, Y Hitchcock, DG Kirsch.
  • Toxicities and survival of elderly patients with muscle-invasive bladder cancer treated with definitive bladder preservation therapy. D Lindsay,  J Kharofa, C Lawton, K Bylow, P Langenstroer, W See, D Wang.
  • Significant reduction of salivary gland volumes after the first two-week standard fractionation IMRT for head and neck cancer. J Yi, E Ahunbay, XA Li, C Shultz, D Wang.
  • Evaluation of neoadjuvant therapy response in adult soft tissue sarcoma using dynamic contrast-enhanced MRI. M Bedi, M Prah, ES Paulson.
  • Stereotactic body radiotherapy for the treatment of elderly patients with medically inoperable pancreatic cancer: A safe and effective radiation therapy. R Yechieli, JR Robbins, M Mahan, F Siddiqui, MA Ajlouni.
  • A novel approach for establishing benchmark CBCT/CT deformable image registration in prostate cancer radiotherapy. J Kim, S Kumar, C Liu, H Zhong, JR Robbins, D Pradhan, M Elshaikh, IJ Chetty.
  • An analysis of rapid review cases that failed to meet the RTOG 1005 contouring and dose volume criteria. XA Li, T Giaddui, W Chen, Y Cui, S McNulty, G Freedman, J Galvin, D Arthur, F Vicini, J White.
  • Dose dependent CT number changes in both tumor and normal lung observed during radiotherapy for lung cancer. C Yang, F Liu, E Gore, C Johnstone, XA Li.
  • A method to determine individualized prescription for biologically adaptive radiation therapy of lung. A Tai, XA Li.
  • Interfraction relative volume changes and independent motions between multiple targets in lung cancer radiotherapy. F Liu, A Tai, E Ahunbay, E Gore, C Johnstone, XA Li.
  • Changes in lumpectomy cavity from initial whole breast irradiation to sequential boost. Q Qiao, X Chen, A Currey, A DeVries, T Kelly, JF Wilson, XA Li.
  • Partial volume effect corrected metabolically active tumor volume from PET for early stage lung cancer. E Dalah, C Yang, E Paulson, K Kainz, E Gore, R Hellman, XA Li.
  • Optimizing CT acquisition for prostate cancer radiation treatment planning and delivery. G Chen, A Tai, F Liu, C Lawton, XA Li.
  • Normal tissue complication probability for radiation-induced trismus after re-irradiation with IMRT for locally recurrent nasopharyngeal carcinoma. Q Zhou, F Han, A Tai, P Prior, S Huang, XA Li, X Deng.
  • Tumor control probability after re-irradiation using intensity modulated radiotherapy for locally recurrent nasopharyngeal carcinoma. Q Zhou, F Han, A Tai, P Prior, S Huang, XA Li, X Deng.
  • Inferior clinical outcomes for patients with positive post-radiotherapy prostate biopsy: Results from prospective randomized trial RTOG 94-08. D Krauss, JP Bahary, L Souhami, E Gore, SMJ Chafe, M Leibenhaut, S Narayan, DG McGowan, CU Jones.
  • Consensus contours for CT vs MRI in image-based brachytherapy for cervix cancer to generate an RTO Atlas. A Viswanathan, B Erickson, S Beriwal, D D'Souza, E Jones, L Portelance, W Small, C Yasar, D Gaffney, W Bosch.
  • Radiation Therapy Oncology Group (RTOG) 9408: A secondary analysis if the risk of death from second cancers comparing whole pelvic (WP) radiotherapy (RT) to prostate only (PO) RT and neoadjuvant hormonal therapy (NHT) + RT to RT only. M Roach III, D Hunt, CU Jones, JP Bahary, KL Zeitzer, L Souhami, M Leibenhaut, M Rotman, EM Gore, HM Sandler.
  • Do socio-demographic factors affect overall survival in patients with unresectable pancreatic cancer? Results of a secondary analysis of RTOG data. D Sherr, M Lesser, T Rich, CH Crane, JH Suh, DY Song, BA Erickson, W Small, K Winter, B Movsas.
  • Serum testosterone changes in patients treated with radiotherapy alone for prostate cancer on RTOG 9408. RC Nichols, A George, JP Bahary, KL Zeitzer, L Souhami, M Leibenhaut, M Rotman, EM Gore, AG Balogh, CU Jones.

Radiological Society of North America (RSNA)
99th Scientific Assembly and Annual Meeting
December 1-6, 2013

Chicago, IL

  • Methodology for robust MRI simulations with a dedicated MRI scanner in radiation oncology. ES Paulson, B Erickson, C Schultz, XA Li.
webmaster@mcw.edu
© 2014 Medical College of Wisconsin
Page Updated 10/15/2014